Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Treatment of Knee Osteoarthritis With Autologous Mesenchymal Stem Cells (KDD&MSV)

This study has been completed.
Fundacion Teknon, Centro Medico Teknon, Barcelona
University of Valladolid
Centro en Red de Medicina Regenerativa de Castilla y Leon
Institut de Terapia Regenerativa Tissular
EGARSAT Suma Intermutual, Barcelona, Spain
Cetir Sant Jordi, S.a..
Information provided by (Responsible Party):
Red de Terapia Celular Identifier:
First received: August 13, 2010
Last updated: January 7, 2015
Last verified: January 2015
In this prospective study we aim to evaluate the feasibility and safety of the implantation of 40 millions MSV in knees with osteoarthritis of grade II-IV (Kellgren and Lawrence). The working hypothesis proposes that MSV antiinflammatory effect will help healing of articular cartilage degeneration to a grade enough to be objectivized by questionnaires and imaging procedures. The study of quantitative changes in structure and composition of cartilage determined by MRI T2-mapping (Cartigram ) will be performed at 6, 12 and 24 months. Pain and disability will be assessed by visual analogue scale (VAS), WOMAC, Lequesne Index and evaluation of the quality of life by Short Form 36 questionnaire (SF-36) completed at 3, 6,12 and 24 months.

Condition Intervention Phase
Osteoarthritis, Knee
Knee Degenerative Disease
Knee Osteoarthritis
Other: Autologous bone marrow mesenchymal stem cells (MSV)
Phase 1
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Regeneration of Articular Cartilage in Grade II, III and IV Knee Osteoarthritis by Intraarticular Injection of Autologous Bone Marrow Stem Cells Expanded ex Vivo With a GMP Procedure Developed by IBGM-Valladolid (MSV)

Resource links provided by NLM:

Further study details as provided by Red de Terapia Celular:

Primary Outcome Measures:
  • Feasibility and Safety of the Implementation of MSV in the Treatment of Osteoarthritis of the Knee. [ Time Frame: 0, 3, 6, 12 and 24 months ]

    Clinical review, questionaires (VAS - Visual Analogue Scale (a psychometric response scale which can be used for subjective measurements of knee pain), WOMAC - Western Ontario and McMaster Universities Osteoarthritis Index (questionnaire to quantify the pain, stiffness and physical function in patients with osteoarthritis of the knee or hip), Lequesne Index (is a composite measure of pain and disability, with specific self-report questionnaires for knee (osteoarthritis)), SF36 life quality - Short Form 36 (is a questionnaire for the detection of changes in quality of life)).

    In all cases, the scale was from 0 to 100%. Measurements were performed before cell transplantation (0) and 3, 6, 12 and 24 months afterwards depending on the questionnaire. For VAS, WOMAC and Lequesne, lower values represent a better outcome. For SF-36, higher values represent a better outcome.

    VAS-DA, VAS for pain associated to daily activities. VAS-SP, VAS for pain associated to sports activities.

Secondary Outcome Measures:
  • Indication of Efficacy [ Time Frame: 0, 6, 12, 24 months ]

    Clinical exploration, questionaires (VAS, WOMAC, Lequesne Index, SF-36 life quality) at all the periods. To evaluate effectiveness through development of criteria for quantitative MRI (Cartigram) denoting regeneration of articular cartilage at 6, 12 and 24 months after the implantation of MSV.

    Magnetic Resonance imaging measurements of T2 relaxation (Cartigram) performed at 0, 6 and 12 months to quantify articular cartilage degeneration. The values (in milliseconds) are T1/2 for decay of the T2 MRI signals. Normal values are below 50 ms; values above 50 ms correspond to inflamed cartilage.

    Mean (SD) are expressed as the percent of values (of a total of 88 measurements) that are between 50 and 90 ms. A value =5 is considered normal (can be attained by chance). Values above 5 are considered pathological. The worst possible is 100.

Enrollment: 12
Study Start Date: May 2010
Study Completion Date: September 2014
Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MSV autologous transplantation
Bone marrow collected from patient will be used for mesenchymal stem cells isolation and expansion under GMP conditions at IBGM-Valladolid (MSV). Autologous MSV implanted in knee by articular injection
Other: Autologous bone marrow mesenchymal stem cells (MSV)
Bone marrow collection from patient, mesenchymal cells isolation and expansion under GMP conditions following the IBGM-Valladolid protocol (MSV). Autologous MSV implantation by articular injection.
Other Name: MSV, mesenchymal stem cells by IBGM-Valladolid protocol.

  Show Detailed Description


Ages Eligible for Study:   18 Years to 76 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Knee osteoarthritis grade II, III and IV of Kellgren and Lawrence assessed by two observers.
  • Chronic knee pain with mechanical characteristics.
  • No local or systemic septic process.
  • Haematological and biochemical analysis without significant alterations that contraindicate treatment.
  • Informed written consent of the patient.
  • The patient is able to understand the nature of the study

Exclusion Criteria:

  • Age over 75 or under 18 years or legally dependent
  • Any sign of infection
  • Positive serology for HIV-1 or HIV-2, Hepatitis B (HBsAg, Anti-HCV-Ab), Hepatitis C (Anti-HCV-Ab) and syphilis.
  • Congenital or acquired malformation resulting in significant deformity of the knee and leading to problems in application or evaluation of results.
  • Overweight expressed as body mass index (BMI) greater than 30.5 (obesity grade II). BMI estimated as mass (kg) / corporal surface (m2).
  • Women who are pregnant or intend to become pregnant or breast-feeding
  • Neoplasia
  • Immunosuppressive states
  • Participation in another clinical trial or treatment with a different investigational product within 30 days prior to inclusion in the study.
  • Other pathologic conditions or circumstances that difficult participation in the study according to medical criteria
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01183728

Teknon Medical Center, ITRT
Barcelona, Spain, 08022
Instituto de Biologia y Genetica Molecular (IBGM), University of Valladolid
Valladolid, Spain, 47003
Sponsors and Collaborators
Red de Terapia Celular
Fundacion Teknon, Centro Medico Teknon, Barcelona
University of Valladolid
Centro en Red de Medicina Regenerativa de Castilla y Leon
Institut de Terapia Regenerativa Tissular
EGARSAT Suma Intermutual, Barcelona, Spain
Cetir Sant Jordi, S.a..
Principal Investigator: Luis Orozco, MD, PhD Fundacion Teknon
Study Director: Ana Sanchez, MD, PhD IBGM, University of Valladolid
Study Director: Robert Soler, MD Institut de Teràpia Regenerativa Tissular, Centro Médico Teknon
Study Director: Javier Garcia-Sancho, MD, PhD IBGM, University of Valladolid
  More Information

Additional Information:
Responsible Party: Red de Terapia Celular Identifier: NCT01183728     History of Changes
Other Study ID Numbers: TerCel001
Eudra-CT 2009-017405-11 ( Other Grant/Funding Number: RD06/0010/0000 )
Protocol Code ( Registry Identifier: MSV-arthro-2009-01 )
Study First Received: August 13, 2010
Results First Received: December 17, 2014
Last Updated: January 7, 2015

Keywords provided by Red de Terapia Celular:
Knee degenerative disease
stem cell
cellular therapy
regenerative therapy
Mesenchymal stem cells
Bone marrow
musculoskeletal Diseases

Additional relevant MeSH terms:
Osteoarthritis, Knee
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases processed this record on May 22, 2017